UNSPSC 51313119: Homochlorcyclizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M1YE3TK8NA, chemically known as (+/-)-homochlorcyclizine dihydrochloride, but more generally known as homochlorcyclizine hydrochloride, which bears US NIH Compound Identifier 32313. European Medicines Agency schedules homochlorcyclizine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG.

Most nations, for tariff purposes, schedule homochlorcyclizine hydrochloride under HS 29339940. SMILES: CN1CCCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.

UNSPSC 51313119 Homochlorcyclizine hydrochloride is a Commodity code that shows limited recent activity aligned with its nominal pharmaceutical scope. State and local procurement under this code encompasses acquisition of pharmaceutical products and drug-related supplies, including naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals for community health and pharmacy benefit programs. The issuing bodies reflect a mix of local health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities across multiple jurisdictions including Oregon). The code shows activity driven primarily by state health agencies and county health departments seeking to support opioid response initiatives and pharmacy benefit management across their jurisdictions.

Recent solicitations are geographically scattered across Florida, Texas, and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 26, 2023 (note: deadline appears dated). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing alternative distribution channels outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Manufacturers responding to MMCAP must maintain compliance with cGMP, the Drug Supply Chain Security Act, and provide detailed National Drug Code information; the RFP weights price competitiveness at 75 percent of evaluation scoring. The code shows scattered rather than concentrated activity, with no clear dominant issuing body or repeat buyer pattern visible in recent postings.